Callan Capital LLC Purchases 8,359 Shares of Haleon plc (NYSE:HLN)

Callan Capital LLC raised its position in Haleon plc (NYSE:HLN) by 30.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,266 shares of the company’s stock after purchasing an additional 8,359 shares during the period. Callan Capital LLC’s holdings in Haleon were worth $346,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HLN. Creative Planning boosted its holdings in Haleon by 15.2% in the 3rd quarter. Creative Planning now owns 285,227 shares of the company’s stock valued at $3,018,000 after purchasing an additional 37,566 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Haleon by 44.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 25,560 shares of the company’s stock valued at $270,000 after purchasing an additional 7,856 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Haleon by 2.0% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 83,589 shares of the company’s stock valued at $881,000 after purchasing an additional 1,646 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Haleon during the 3rd quarter valued at $3,700,000. Finally, Ballentine Partners LLC raised its position in shares of Haleon by 53.1% during the 3rd quarter. Ballentine Partners LLC now owns 22,831 shares of the company’s stock valued at $242,000 after buying an additional 7,918 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Stock Performance

Haleon stock opened at $10.08 on Friday. The stock has a market cap of $45.61 billion, a P/E ratio of 29.63, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. The firm’s fifty day moving average price is $9.56 and its 200-day moving average price is $9.82. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.